Evaluating Stem Cell Function in Patients with Chronic Kidney Disease (CKD)

Overview

  • Study type

    Observational
  • Study IDs

  • Describes the nature of a clinical study. Types include:

    • Observational study — observes people and measures outcomes without affecting results.
    • Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
    • Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
  • Site IRB
    • Rochester, Minnesota: 15-000933
    Sponsor Protocol Number: 15-000933

About this study

New treatments of the future may use stem cells, cells that naturally occur in our blood or belly/abdominal fat, to help people with kidney disease.  The purpose of this study is to understand the function of specific cell types and how well they may work to repair our kidneys.  Two cell groups, mesenchymal stem cells (MSCs) and endothelial progenitor cells (EPCs), will be examined.  Study participants will include individuals with varying degrees of kidney function and potential causes of kidney disease.  This information will help plan for future studies using stem cells to treat kidney disease.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.

See eligibility criteria

Inclusion Criteria:

All subjects eligible for this study will meet the following inclusion criteria:

  • Age between 18 to 100 years
  • Ability to provide consent and complete all aspects of the study

Exclusion Criteria: 

Subjects will be excluded from participation if they have any of the following exclusion criteria:

  • Pregnant
  • Evidence of hepatitis B or C, or HIV infection
  • Solid organ transplantation
  • Nephrotic syndrome
  • Immunosuppression therapy
  • Active glomerulonephritis
  • HbA1c ≥11%
  • Subjects on therapeutic doses of anticoagulants [Warfarin (Coumadin), Rivaroxaban (Xarleto); Apixaban (Eliquis); Dabigatran (Pradaxa, Prazaxa)]
  • History of substance abuse (including alcohol) within the past 2 years
  • Active substance abuse (>3 alcoholic beverages/day or >21 per week)
  • Body weight >150 kg or BMI >50
  • Uncontrolled psychiatric disorder

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

LaTonya Hickson, M.D.

Open for enrollment

Contact information:

Jennifer Manggaard CCRP

(507)255-7768

Manggaard.Jennifer@mayo.edu

.
CLS-20199619

Mayo Clinic Footer